Your browser doesn't support javascript.
loading
Hematological prognosticators in metastatic renal cell cancer treated with immune checkpoint inhibitors: a meta-analysis.
Yanagisawa, Takafumi; Mori, Keiichiro; Katayama, Satoshi; Mostafaei, Hadi; Quhal, Fahad; Laukhtina, Ekaterina; Rajwa, Pawel; Motlagh, Reza S; Aydh, Abdulmajeed; König, Frederik; Grossmann, Nico C; Pradere, Benjamin; Miki, Jun; Schmidinger, Manuela; Egawa, Shin; Shariat, Shahrokh F.
Affiliation
  • Yanagisawa T; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • Mori K; Department of Urology, The Jikei University School of Medicine, Tokyo105-8461, Japan.
  • Katayama S; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • Mostafaei H; Department of Urology, The Jikei University School of Medicine, Tokyo105-8461, Japan.
  • Quhal F; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • Laukhtina E; Department of Urology, Okayama University Graduate School of Medicine, Dentistry & Pharmaceutical Sciences, Okayama, 700-8558, Japan.
  • Rajwa P; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • Motlagh RS; Research Center for Evidence Based Medicine, Tabriz University of Medical Sciences, Tabriz, 5166, Iran.
  • Aydh A; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • König F; Department of Urology, King Fahad Specialist Hospital, Dammam, 32253, Saudi Arabia.
  • Grossmann NC; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • Pradere B; Institute for Urology & Reproductive Health, Sechenov University, Moscow, 119991, Russia.
  • Miki J; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • Schmidinger M; Department of Urology, Medical University of Silesia, Zabrze, 41-808, Poland.
  • Egawa S; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, 1090, Austria.
  • Shariat SF; Men's Health & Reproductive Health Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Immunotherapy ; 14(9): 709-725, 2022 06.
Article in En | MEDLINE | ID: mdl-35465726
Identifying the predictive/prognostic factors that can be applied to daily clinical practice is mandatory to facilitate the use of immune checkpoint inhibitors. Some pretreatment hematological markers used in daily clinical practice appear to be prognostic factors in metastatic renal cell carcinoma patients treated with immune checkpoint inhibitors. We believe that the findings of the present meta-analysis might help researchers to design prospective correlative biomarker studies to guide clinical decision-making in the immunotherapy era.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Immunotherapy Journal subject: ALERGIA E IMUNOLOGIA / TERAPEUTICA Year: 2022 Type: Article Affiliation country: Austria
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Renal Cell / Kidney Neoplasms Type of study: Diagnostic_studies / Prognostic_studies / Systematic_reviews Limits: Humans Language: En Journal: Immunotherapy Journal subject: ALERGIA E IMUNOLOGIA / TERAPEUTICA Year: 2022 Type: Article Affiliation country: Austria